Indaptus Therapeutics (INDP) Insider Trading & Ownership $9.89 -0.57 (-5.45%) Closing price 03:59 PM EasternExtended Trading$10.12 +0.23 (+2.33%) As of 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock Indaptus Therapeutics (NASDAQ:INDP) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage20.80%Number OfInsiders Buying(Last 3 Years)4Amount OfInsider Buying(Last 3 Years)$191.86KNumber OfInsiders Selling(Last 3 Years)0 Get INDP Insider Trade Alerts Want to know when executives and insiders are buying or selling Indaptus Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address INDP Insider Buying and Selling by Quarter Indaptus Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails8/14/2023Glen R AndersonMajor ShareholderBuy854$65.52$55,954.08 8/10/2023Glen R AndersonMajor ShareholderBuy1,584$54.32$86,042.88 12/1/2022Boyan Vesselinov LitchevInsiderBuy17$52.36$890.12 11/22/2022Boyan Vesselinov LitchevInsiderBuy17$51.24$871.08 11/21/2022Jeffrey A MecklerCEOBuy342$53.20$18,194.40 11/18/2022Jeffrey A MecklerCEOBuy14$49.28$689.92 9/8/2022Jeffrey A MecklerCEOBuy368$78.40$28,851.20 9/7/2022Walt Addison LinscottInsiderBuy5$73.36$366.80 (Data available from 1/1/2013 forward) INDP Insider Trading Activity - Frequently Asked Questions Who is on Indaptus Therapeutics' Insider Roster? The list of insiders at Indaptus Therapeutics includes Boyan Vesselinov Litchev, Glen R Anderson, Jeffrey A Meckler, and Walt Addison Linscott. Learn more on insiders at INDP. What percentage of Indaptus Therapeutics stock is owned by insiders? 20.80% of Indaptus Therapeutics stock is owned by insiders. Learn more on INDP's insider holdings. Which Indaptus Therapeutics insiders have been buying company stock? The following insider purchased INDP shares in the last 24 months: Glen R Anderson ($141,996.96). How much insider buying is happening at Indaptus Therapeutics? Insiders have purchased a total of 2,438 INDP shares in the last 24 months for a total of $141,996.96 bought. Indaptus Therapeutics Key ExecutivesMr. Jeffrey A. Meckler (Age 57)CEO & Director Compensation: $867.03kDr. Michael J. Newman Ph.D. (Age 68)Founder, Chief Scientific Officer & Director Compensation: $659.99kMr. Walt Addison Linscott Esq. (Age 63)Chief Operating Officer Compensation: $716.35kMr. Nir Sassi (Age 48)CFO, Secretary & Treasurer Compensation: $378.47kDr. Roger J. Waltzman M.B.A. (Age 56)M.D., Chief Medical Officer More Insider Trading Tools from MarketBeat Related Companies Moleculin Biotech Insider Transactions Tempest Therapeutics Insider Transactions Cingulate Insider Transactions Aytu BioPharma Insider Transactions Chemomab Therapeutics Insider Transactions Relmada Therapeutics Insider Transactions Cadrenal Therapeutics Insider Transactions Rallybio Insider Transactions BioAtla Insider Transactions Finch Therapeutics Group Insider Transactions Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles The Bottom Is in For These 3 Small-Cap Stocks Insiders Are Buying3 Catalysts Driving Plug Power’s Turnaround CaseInsider Selling Hits Market Leaders—Should You Be Worried?Insiders Spent Millions on These 3 Stocks Over the Past 2 Months3 Small Caps Drawing Insider and Institutional Support This page (NASDAQ:INDP) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersElon Just Fired the IRS Agents Targeting Your SavingsElon Musk just fired 6,700 IRS agents — and exposed a war on your retirement. While D.C. scrambles to regai...Priority Gold | SponsoredWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredTrump’s Endgame? (R.I.P. China)Tucked inside a Silicon Valley factory, a bold new tech is quietly emerging—one that could ignite a $12 trilli...Brownstone Research | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredBitcoin Beats Gold — But This Coin Could Beat Them BothBitcoin just hit a record high—but it’s not the top crypto play right now. Crypto analyst Juan Villaverde, ...Weiss Ratings | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Indaptus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Indaptus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.